jrnls.org logo
Submit

BROWSE ALL JOURNALS

SEE ALL 19 JOURNALS
Indian Journal of Pharmaceutical Education and ResearchNOW IN
Review

An Overview of Dual Targeting Nanostructured Lipid Carriers for the Treatment of Ovarian Cancer

Praharsh Kumar Mandadhi Rajendra1, Natarajan Jawahar1★, Rajeshkumar Raman2, Hagalavadi Nanjappa Shivakumar3, Anjali Puthusserikkunnu Balan1★ Corresponding author

  1. 1Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, INDIA.
  2. 2Department of Pharmaceutical Biotechnology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, INDIA.
  3. 3Department of Pharmaceutics, KLE College of Pharmacy, Bengaluru, Karnataka, INDIA.

CORRESPONDENCE

Natarajan Jawahar

Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, INDIA.

jawahar.n@jssuni.edu.in

Received: 01-07-2020; Revised: 02-12-2020; Accepted: 01-03-2021.

Volume 55, Issue 2 · pp. 330–335 · PUBLISHED 2021 · DOI: 10.5530/ijper.55.2.70

View on IJPER original site ↗

ABSTRACT

Purpose: To summarize main findings from research on oral delivery of Nanostructured lipid carriers targeting ovarian cancer. Methods: A narrative review of all the relevant papers known to author was conducted. Results: Ovarian cancer is one of the most common gynaecologic cancer, the frontline treatments for which are surgical approach followed by radiotherapy or chemotherapy. Chemotherapy has its own limitations; consequently, there is a need to develop a targeted drug delivery system with high efficacy. Preclinical evidence suggests that combination therapies are likely to be effective in ovarian cancer. However, from clinical reports, it is evident that chemotherapeutic drugs have lower therapeutic value for the treatment of ovarian cancer. We propose that these limitations can be overcome by a novel formulation consisting of nanostructured lipid carriers. Recent pharmacological research has successfully potentiated the effects of combination therapy in acute animal preparations by inhibiting proteins that are involved in different physiological pathways of cancer cells. Conclusion: We have reviewed the scope of nanostructured lipid carriers concerning chemotherapy of ovarian cancer. The advantages of oral administration of these lipid carriers are discussed. Also, the various nano-lipid formulations and combination therapies reported along with their therapeutic outcomes have been reviewed. In light of this, nanostructured lipid carriers containing two different active ingredients for oral administration could be a potential approach for the effective treatment of ovarian cancer.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Rajendra, P. K. M., Jawahar, N., Raman, R., Shivakumar, H. N., & Balan, A. P. (2021). An Overview of Dual Targeting Nanostructured Lipid Carriers for the Treatment of Ovarian Cancer. Indian Journal of Pharmaceutical Education and Research, 55(2), 330–335. https://doi.org/10.5530/ijper.55.2.70